Recommandations en Onco-Urologie 2010 : Cancer du rein

25 novembre 2010

Auteurs : J.-J. Patard, H. Baumert, J.-M. Corréas, B. Escudier, H. Lang, J.-A. Long, Y. Neuzillet, P. Paparel, L. Poissonnier, N. Rioux-Leclercq, M. Soulié
Référence : Prog Urol, 2010, 20, S319, suppl. S4




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Particularités de dépistage et de traitement des formes héréditaires de cancer du rein



Cussenot O., Fournier G. Genetics and urology Prog Urol 2000 ;  10 : 681-1097
Fournier G., Valeri A., Cussenot O. Familial forms of cancer of the urogenital tract: clinical and genetic features Prog Urol 1996 ;  6 : 343-355
Valeri A., Cussenot O. Hereditary forms of kidney cancer and genetic screening Prog Urol 2003 ;  13 : 1201-1204
Glenn G.M., Daniel L.N., Choyke P., Linehan W.M., Oldfield E., Gorin M.B., et al. Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus Hum Genet 1991 ;  87 : 207-210 [cross-ref]
Poulsen M.L., Budtz-Jorgensen E., Bisgaard M.L. Surveillance in von Hippel-Lindau disease (vHL) Clin Genet 2010 ;  77 : 49-59 [cross-ref]
Choyke P.L., Glenn G.M., Walther M.M., Zbar B., Weiss G.H., Alexander R.B., et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients AJR Am J Roentgenol 1992 ;  159 : 1229-1234 [cross-ref]
Novick A.C., Streem S.B. Long-term followup after nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease J Urol 1992 ;  147 : 1488-1490 [cross-ref]
Walther M.M., Choyke P.L., Weiss G., Manolatos C., Long J., Reiter R., et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma J Urol 1995 ;  153 : 913-916 [cross-ref]
Park B.K., Kim C.K. CT-guided radiofrequency ablation of a renal tumor abutting vascular pedicle in a patient with von Hippel Lindau disease Cardiovasc Intervent Radiol 2009 ;  32 : 840-842 [cross-ref]
Coleman J.A., Russo P. Hereditary and familial kidney cancer Curr Opin Urol 2009 ;  19 : 478-485 [cross-ref]

Classification et systèmes pronostiques



Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer  : Wiley-Blackwell (2009). 255-7.
Lam J.S., Klatte T., Kim H.L., Patard J.J., Breda A., Zisman A., et al. Prognostic factors and selection for clinical studies of patients with kidney cancer Crit Rev Oncol Hematol 2008 ;  65 : 235-262 [cross-ref]
Sorbellini M., Kattan M.W., Snyder M.E., Reuter V., Motzer R., Goetzl M., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma J Urol 2005 ;  173 : 48-51 [cross-ref]
Zisman A., Pantuck A.J., Dorey F., Said J.W., Shvarts O., Quintana D., et al. Improved prognostication of renal cell carcinoma using an integrated staging system Journal of Clinical Oncology 2001 ;  19 : 1649-1657 [cross-ref]
Frank I., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 2002 ;  168 : 2395-2400 [cross-ref]
Leibovich B.C., Blute M.L., Cheville J.C., Lohse C.M., Frank I., Kwon E.D., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials Cancer 2003 ;  97 : 1663-1671 [cross-ref]
Patard J.J., Kim H.L., Lam J.S., Dorey F.J., Pantuck A.J., Zisman A., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study J Clin Oncol 2004 ;  22 : 3316-3322 [cross-ref]
Karakiewicz P.I., Briganti A., Chun F.K.H., Trinh Q.-D., Perrotte P., Ficarra V., et al. Multi-Institutional Validation of a New Renal Cancer-Specific Survival Nomogram J Clin Oncol 2007 ;  25 : 1316-1322 [cross-ref]
Zigeuner R., Hutterer G., Chromecki T., Imamovic A., Kampel-Kettner K., Rehak P., et al. External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology Eur Urol 2010 ;  57 : 102-109
Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma J Clin Oncol 2002 ;  20 : 289-296 [cross-ref]
Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 2009 ;  27 : 5794-5799 [cross-ref]
Isbarn H., Karakiewicz P.I. Predicting cancer-control outcomes in patients with renal cell carcinoma Curr Opin Urol 2009 ;  19 : 247-257 [cross-ref]
Raj G.V., Thompson R.H., Leibovich B.C., Blute M.L., Russo P., Kattan M.W. Preoperative nomogram predicting 12-year probability of metastatic renal cancer J Urol 2008 ;  179 : 2146-2151discussion 2151.
 [cross-ref]
Karakiewicz P.I., Suardi N., Capitanio U., Jeldres C., Ficarra V., Cindolo L., et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma Eur Urol 2009 ;  55 : 287-295 [cross-ref]

Recommandations histopathologiques



Lopez-Beltran A., Scarpelli M., Kirkali Z. 2004 WHO classification of the renal tumors of the adults Eur Urol 2006 ;  49 : 798-805 [cross-ref]
Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours Lyons: IARC Press (2004). 
7
Zhao H., Ljungberg B., Grankvist K., Rasmuson T., Tibshirani R., Brooks J.D. Gene expression profiling predicts survival in conventional renal cell carcinoma PLoS Med 2006 ;  3 : e13
Grignon D.J., Che M. Clear cell renal cell carcinoma Clin Lab Med 2005 ;  25 : 305-316 [inter-ref]
Delahunt B., Eble J.N., McCredie M.R., Bethwaite P.B., Stewart J.H., Bilous A.M. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases Hum Pathol 2001 ;  32 : 590-595 [cross-ref]
Amin M.B., Paner G.P., Alvarado-Cabrero I., Young A.N., Stricker H.J., Lyles R.H., et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases Am J Surg Pathol 2008 ;  32 : 1822-1834 [cross-ref]
Argani P., Lal P., Hutchinson B., Lui M.Y., Reuter V.E., Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay Am J Surg Pathol 2003 ;  27 : 750-761 [cross-ref]
Nassir A., Jollimore J., Gupta R., Bell D., Norman R. Multilocular cystic renal cell carcinoma: a series of 12 cases and review of the literature Urology 2002 ;  60 : 421-427 [inter-ref]
Shen S.S., Ro J.Y., Tamboli P., Truong L.D., Zhai Q., Jung S.J. Mucinous tubular and spindle cell carcinoma is probably a variant of renal papillary carcinoma Ann Diagn Pathol 2007 ;  11 : 13-21 [cross-ref]
Amin M.B., MacLennan G.T., Gupta R., Grignon D., Paraf F., Vieillefond A., et al. Tubulocystic carcinoma of the kidney. Clinicopathologic analysis of 31 cases Am J Surg Pathol 2009 ;  33 : 384-392 [cross-ref]
Zhou M., Kort E., Hoekstra P., Westphal M., Magi-Galluzzi C., Sercia L., et al. Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence Am J Surg Pathol 2009 ;  33 : 72-80 [cross-ref]
Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma Am J Surg Pathol 1982 ;  6 : 655-663
Rioux-Leclercq N., Karakiewicz P.I., Trinh Q.D., Ficarra V., Cindolo L., de la Taille A., et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma Cancer 2007 ;  109 : 868-874 [cross-ref]
Lang H., Lindner V., de Fromont M., Molinie V., Letourneux H., Meyer N., et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with > 15-year follow- up Cancer 2005 ;  103 : 625-629 [cross-ref]

Biopsie des tumeurs du rein



Silverman S.G., Israel G.M., Herts B.R., Richie J.P. Management of the incidental renal mass Radiology 2008 ;  249 : 16-31 [cross-ref]
Rybicki F.J., Shu K.M., Cibas E.S., Fielding J.R., Vansonnenberg E., Silverman S.G. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses AJR Am J Roentgenol 2003 ;  180 : 1281-1287 [cross-ref]
Niceforo J., Coughlin B.F. Diagnosis of renal cell carcinoma: value of fine-needle aspiration cytology in patient with metastases or contraindications to nephrectomy AJR Am J Roentgenol 1993 ;  161 : 1303-1305 [cross-ref]
Méjean A., Correas J.M., Thiounn N., Chretien Y., Helenon O., Dufour B., et al. Traitement conservateur des cancers du rein par cryoablation et radiofréquence Prog Urol 2006 ;  16 : 101-104
Tuncali K., Vansonnenberg E., Shankar S., Mortele K.J., Cibas E.S., Silverman S.G. Evaluation of patients referred for percutaneous ablation of renal tumors: importance of a preprocedural diagnosis AJR Am J Roentgenol 2004 ;  183 : 575-582 [cross-ref]
Neuzillet Y., Lechevallier E., Andre M., Daniel L., Nahon O., Coulange C. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy Urology 2005 ;  66 : 1181-1185 [inter-ref]
Lechevallier E. Core biopsy of solid renal masses under CT guidance Eur Urol 2007 ;  S6 : 540-543 [cross-ref]
Bosniak M.A. The current radiological approach to renal cysts Radiology 1986 ;  158 : 1-10 [cross-ref]
Harisinghani M.G., Maher M.M., Gervais D.A., MCGovern F., Hahn P., Jhaveri K., et al. Incidence of malignancy in complex cystic renal masses (Bosniak category III) : should imaging-guided biopsy precede surgery? AJR Am J Roentgenol 2003 ;  180 : 755-758 [cross-ref]
Slywotsky C., Maya M. Needle tract seeding of transitional cell carcinoma following fine-needle aspiration of renal mass Abdom Imaging 1994 ;  18 : 174-176
Smith P.S., Marshall F.F., Fishman E.K. Spiral computed tomography evaluation of the kidneys: state of the art Urology 1998 ;  51 : 3-11 [inter-ref]
Hergesell O., Felten H., Andrassy K., Kuhn K., Ritz E. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases Nephrol Dial Transplant 1998 ;  13 : 975-977 [cross-ref]
Schmidbauer J., Remzi M., Memarsadeghi M., Haitel A., Klingler H.C., Katzenbeisser D., et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses Eur Urol 2008 ;  53 : 1003-1011 [cross-ref]
Breda A., Treat E.G., Haft-Candell L., Leppert J.T., Harper J.D., Said J., et al. Comparison of accuracy of 14 -, 18 - and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study BJU Int 2010 ;  105 : 940-945 [cross-ref]
Remzi M., Marberger M. Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur Urol 2009 ;  55 : 359-367 [cross-ref]
Silverman S.G., Collick B.D., Figueira M.R., Khorasani R., Adams D.F., Newman R.W., et al. Interactive MR-guided biopsy in an openconfiguration MR imaging system Radiology 1995 ;  197 : 175-181 [cross-ref]
Neuzillet Y., Lechevallier E., Andre M., Daniel L., Coulange C. Accuracy and clinical role of the fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses J Urol 2004 ;  271 : 1802-1805 [cross-ref]
Mejean A., Correas J.M., Escudier B., De Fromont M., Lang H., Long J.A., et al. Cancer du rein Prog Urol 2007 ;  17 : 1101-1144 [cross-ref]

Prise en charge des tumeurs kystiques



Terada N., Ichioka K., Matsuta Y., Okubo K., Yoshimura K., Arai Y. The natural history of simple renal cysts J Urol 2002 ;  167 : 21-23 [cross-ref]
Israel G.M., Hindman N., Bosniak M.A. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system Radiology 2004 ;  231 : 365-371 [cross-ref]
Israel G.M., Bosniak M.A. An update of the Bosniak renal cyst classification system Urology 2005 ;  66 : 484-488 [inter-ref]
Park B.K., Kim B., Kim S.H., Ko K., Lee H.M., Choi H.Y. Assessment of cystic renal masses based on Bosniak classification: comparison of CT and contrast-enhanced US Eur J Radiol 2007 ;  61 : 310-314 [cross-ref]
Israel G.M., Bosniak M.A. Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF) AJR Am J Roentgenol 2003 ;  181 : 627-633 [cross-ref]
Shiraishi K., Eguchi S., Mohri J., Kamiryo Y. Laparoscopic decortication of symptomatic simple renal cysts: 10-year experience from one institution BJU Int 2006 ;  98 : 405-408 [cross-ref]
Hartman D.S., Davis C.J., Johns T., Goldman S.M. Cystic renal cell carcinoma Urology 1986 ;  28 : 145-153 [cross-ref]
Madewell J.E., Goldman S.M., Davis C.J., Hartman D.S., Feigin D.S., Lichtenstein J.E. Multilocular cystic nephroma: a radiographicpathologic correlation of 58 patients Radiology 1983 ;  146 : 309-321 [cross-ref]
Spaliviero M., Herts B.R., Magi-Galluzzi C., Xu M., Desai M.M., Kaouk J.H., et al. Laparoscopic partial nephrectomy for cystic masses J Urol 2005 ;  174 : 614-619 [cross-ref]
Koga S., Nishikido M., Hayashi T., Matsuya F., Saito Y., Kanetake H. Outcome of surgery in cystic renal cell carcinoma Urology 2000 ;  56 : 67-70 [inter-ref]

Prise en charge des tumeurs rénales non métastatiques



Gill I.S., Matin S.F., Desai M.M., Kaouk J.H., Steinberg A., Mascha E., et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients J Urol 2003 ;  170 : 64-68 [cross-ref]
Gill I.S., Kavoussi L.R., Lane B.R., Blute M.L., Babineau D., Colombo J.R., et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors J Urol 2007 ;  178 : 41-46 [cross-ref]
Porpiglia F., Volpe A., Billia M., Scarpa R.M. Laparoscopic versus open partial nephrectomy: analysis of the current literatura Eur Urol 2008 ;  53 : 732-743 [cross-ref]
Venkatesh R., Weld K., Ames C.D., Figenshau S.R., Sundaram C.P., Andriole G.L., et al. Laparoscopic partial nephrectomy for renal masses: effect of tumor location Urology 2006 ;  67 : 1169-1174discussion 1174.
 [inter-ref]
Gill I.S., Kamoi K., Aron M., Desai M.M. 800 Laparoscopic partial nephrectomies: a single surgeon series J Urol 2010 ;  183 : 34-41 [cross-ref]
Lifshitz D.A., Shikanov S., Jeldres C., Deklaj T., Karakiewicz P.I., Zorn K.C., et al. Laparoscopic partial nephrectomy: predictors of prolonged warm ischemia J Urol 2009 ;  182 : 860-865 [cross-ref]
Baumert H., Ballaro A., Shah N., Mansouri D., Zafar N., Molinié V., et al. Reducing warm ischaemia time during laparoscopic partial nephrectomy: a prospective comparison of two renal closure techniques Eur Urol 2007 ;  52 : 1164-1169 [cross-ref]
Nguyen M.M., Gill I.S. Halving ischemia time during laparoscopic partial nephrectomy J Urol 2008 ;  179 : 627-632discussion 632.
 [cross-ref]
Lane B.R., Gill I.S. 7-year oncological outcomes after laparoscopic and open partial nephrectomy J Urol 2010 ;  183 : 473-479 [cross-ref]
Lane B.R., Novick A.C., Babineau D., Fergany A.F., Kaouk J.H., Gill I.S. Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney J Urol 2008 ;  179 : 847-851discussion 852.
Benway B.M., Bhayani S.B., Rogers C.G., Dulabon L.M., Patel M.N., Lipkin M., et al. Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multiinstitutional analysis of perioperative outcomes J Urol 2009 ;  182 : 866-872 [cross-ref]
Wang A.J., Bhayani S.B. Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of >100 consecutive procedures Urology 2009 ;  73 : 306-310 [cross-ref]
Kural A.R., Atug F., Tufek I., Akpinar H. Robot-assisted partial nephrectomy versus laparoscopic partial nephrectomy: comparison of outcomes J Endourol 2009 ;  23 : 1491-1497 [cross-ref]

La néphrectomie partielle est le traitement curatif à privilégier pour les tumeurs T1



Lerner S.E., Hawkins C.A., Blute M.L., Grabner A., Wollan P.C., Eickholt J.T., et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery J Urol 1996 ;  155 : 1868-1873 [cross-ref]
Herr H.W. Partial nephrectomy for unilateral renal cell carcinoma and a normal controlateral kidney: 10-year followup J Urol 1999 ;  161 : 33-34discussion 34-5.
 [cross-ref]
Fergany A.F., Hafez K.S., Novick A.C. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup J Urol 2000 ;  163 : 442-445 [cross-ref]
Delakas D., Karyotis I., Daskalopoulos G., Terhorst B., Lymberopoulos S., Cranidis A. Nephron sparing surgery for localized renal cell carcinoma with a normal controlateral kidney: a European three center experience Urology 2002 ;  60 : 998-1002 [inter-ref]
Becker F., Siemer S., Humke U., Hack M., Ziegler M., Stöckle M. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: long term survival data of 216 patients Eur Urol 2006 ;  49 : 308-313 [cross-ref]
Antonelli A., Cozzoli A., Nicolai M., Zani D., Zanotelli T., Perucchini L., et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm Eur Urol 2008 ;  53 : 803-809 [cross-ref]
Dash A., Vickers A.J., Schachter L.R., Bach A.M., Snyder M.E., Russo P. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm BJU Int 2006 ;  97 : 939-945 [cross-ref]
Leibovich B.C., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy J Urol 2004 ;  171 : 1066-1070 [cross-ref]
Pahernik S., Roos F., Rohrig B., Wiesner C., Thuroff J.W. Elective nephron sparing surgery for renal cell carcinoma larger than 4cm J Urol 2008 ;  179 : 71-74 [cross-ref]
Patard J.J., Pantuck A.J., Crepel M., Lam J.S., Bellec L., Albouy B., et al. Morbidity and clinical outcome of nephron sparing surgery in relation to tumour size and indication Eur Urol 2007 ;  52 : 148-154 [cross-ref]
Crepel M., Jeldres C., Perrotte P., Capitanio U., Isbarn H., Shariat S.F., et al. Nephron-sparing surgery is equally effective to radical nephrectomy for T1bN0M0 renal cell carcinoma: a population-based assessment Urology 2010 ;  75 : 271-275 [cross-ref]
Peycelon M., Hupertan V., Comperat E., Renard-Penna R., Vaessen C., Conort P., et al. Long term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm J Urol 2009 ;  181 : 35-41 [cross-ref]
Raz O., Mendlovic S., Shilo Y., Leibovici D., Sandbank J., Lindner A., et al. Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery Urology 2010 ;  75 : 277-280 [inter-ref]
Bensalah K., Pantuck A.J., Rioux-Leclercq N., Thuret R., Montorsi F., Karakiewicz P.I., et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery Eur Urol 2010 ;  57 : 466-471 [cross-ref]
Yossepowitch O., Thompson R.H., Leibovich B.C., Eggener S.E., Pettus J.A., Kwon E.D., et al. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes J Urol 2008 ;  179 : 2158-2163 [cross-ref]
Thompson R.H., Boorjian S.A., Lohse C.M., Leibovich B.C., Kwon E.D., Cheville J.C., et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy J Urol 2008 ;  179 : 468-471discussion 472-3.
 [cross-ref]
Huang W.C., Elkin E.B., Levey A.S., Jang T.L., Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes? J Urol 2009 ;  181 : 55-61discussion 61-2.
 [cross-ref]
Miller D.C., Schonlau M., Litwin M.S., Lai J., Saigal C.S. Urologic Diseases in America Project. Renal and cardiovascular morbidity after partial or radical nephrectomy Cancer 2008 ;  112 : 511-520 [cross-ref]
Zini L., Perrotte P., Capitanio U., Jeldres C., Shariat S.F., Antebi E., et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality Cancer 2009 ;  115 : 1465-1471 [cross-ref]
Van Poppel H., Da Pozzo L., Albrecht W., Matveev V., Bono A., Borkowski A., et al. European Organization for Research and Treatment of Cancer (EORTC) ; National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) ; Southwest Oncology Group (SWOG) ; Eastern Cooperative Oncology Group (ECOG). A prospective randomized EORTC interGroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low stage renal cell carcinoma Eur Urol 2007 ;  51 : 1606-1615 [cross-ref]
Thompson R.H., Frank I., Lohse C.M., Saad I.R., Fergany A., Zincke H., et al. The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi institutional study J Urol 2007 ;  177 : 471-476 [cross-ref]
Pasticier G., Timsit M.O., Badet L., De La Torre Abril L., Halila M., Fassi Fehri H., et al. Nephron-sparing surgery for renal cell carcinoma: detailed analysis of complications over a 15-year period Eur Urol 2006 ;  49 : 485-490 [cross-ref]

Place des traitements ablatifs



Lin Y.C., Turna B., Frota R., Aron M., Haber G.P., Kamoi K., et al. Laparoscopic partial nephrectomy versus laparoscopic cryoablation for multiple ipsilateral renal tumors Eur Urol 2008 ;  53 : 1210-1216 [cross-ref]
Mylona S., Kokkinaki A., Pomoni M., Galani P., Ntai S., Thanos L. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with solitary kidney: 6 years experience Eur J Radiol 2009 ;  69 : 351-356 [cross-ref]
Hacker A., Chauhan S., Peters K., Hildenbrand R., Marlinghaus E., Alken P., et al. Multiple high-intensity focused ultrasound probes for kidney-tissue ablation J Endourol 2005 ;  19 : 1036-1040 [cross-ref]
Clark P.E., Woodruff R.D., Zagoria R.J., Hall M.C. Microwave ablation of renal parenchymal tumors before nephrectomy: phase I study AJR Am J Roentgenol 2007 ;  188 : 1212-1214 [cross-ref]
Klingler H.C., Susani M., Seip R., Mauermann J., Sanghvi N., Marberger M.J. A novel approach to energy ablative therapy of small renal tumours: laparoscopic high-intensity focused ultrasound Eur Urol 2008 ;  53 : 810-816discussion 817-8.
Weight C.J., Kaouk J.H., Hegarty N.J., Remer E.M., O’Malley C.M., Lane B.R., et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors J Urol 2008 ;  179 : 1277-1281discussion 1281-73.
 [cross-ref]
Gill I.S., Remer E.M., Hasan W.A., Strzempkowski B., Spaliviero M., Steinberg A.P., et al. Renal cryoablation: outcome at 3 years J Urol 2005 ;  173 : 1903-1907 [cross-ref]
Varkarakis I.M., Allaf M.E., Inagaki T., Bhayani S.B., Chan D.Y., Su L.M., et al. Percutaneous radio frequency ablation of renal masses: results at a 2-year mean followup J Urol 2005 ;  174 : 456-460discussion 460.
 [cross-ref]
Hui G.C., Tuncali K., Tatli S., Morrison P.R., Silverman S.G. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates J Vasc Interv Radiol 2008 ;  19 : 1311-1320 [cross-ref]
Bird V.G., Carey R.I., Ayyathurai R., Bird V.Y. Management of Renal Masses with Laparoscopic-Guided Radiofrequency Ablation versus Laparoscopic Partial Nephrectomy J Endourol 2009 ;  23 : 81-88 [cross-ref]
Sterrett S.P., Nakada S.Y., Wingo M.S., Williams S.K., Leveillee R.J. Renal thermal ablative therapy Urol Cl in North Am 2008 ;  35 : 397-414viii.
 [inter-ref]
Matin S.F., Ahrar K., Cadeddu J.A., Gervais D.A., McGovern F.J., Zagoria R.J., et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study J Urol 2006 ;  176 : 1973-1977 [cross-ref]
Kunkle D.A., Uzzo R.G. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis Cancer 2008 ;  113 : 2671-2680 [cross-ref]
Kunkle D.A., Egleston B.L., Uzzo R.G. Excise, ablate or observe: the small renal mass dilemma – -a meta-analysis and review J Urol 2008 ;  179 : 1227-1233discussion 1233-24.
 [cross-ref]
Desai M.M., Aron M., Gill I.S. Laparoscopic partial nephrectomy versus laparoscopic cryoablation for the small renal tumor Urology 2005 ;  66 : 23-28 [inter-ref]
Chawla S.N., Crispen P.L., Hanlon A.L., Greenberg R.E., Chen D.Y., Uzzo R.G. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature J Urol 2006 ;  175 : 425-431 [cross-ref]
Beisland C., Hjelle K.M., Reisaeter L.A., Bostad L. Observation Should be Considered as an Alternative in Management of Renal Masses in Older and Comorbid Patients Eur Urol 2009 ;  55 : 1419-1427 [cross-ref]

Surveillance active



Abouassaly R., Lane B.R., Novick A.C. Active surveillance of renal masses in elderly patients J Urol 2008 ;  180 : 505-508discussion 508-9.
 [cross-ref]
Kunkle D.A., Crispen P.L., Chen D.Y., Greenberg R.E., Uzzo R.G. Enhancing renal masses with zero net growth during active surveillance J Urol 2007 ;  177 : 849-853discussion 853-44.
 [cross-ref]
Chawla S.N., Crispen P.L., Hanlon A.L., Greenberg R.E., Chen D.Y., Uzzo R.G. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature J Urol 2006 ;  175 : 425-431 [cross-ref]
Van Poppel H., Joniau S. Is surveillance an option for the treatment of small renal masses? Eur Urol 2007 ;  52 : 1323-1330 [cross-ref]
Crispen P.L., Viterbo R., Boorjian S.A., Greenberg R.E., Chen D.Y., Uzzo R.G. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance Cancer 2009 ;  115 : 2844-2852 [cross-ref]
Kunkle D.A., Egleston B.L., Uzzo R.G. Excise, ablate or observe: the small renal mass dilemma – -a meta-analysis and review J Urol 2008 ;  179 : 1227-1233discussion 1233-24.
 [cross-ref]

Organigramme de prise en charge des petites tumeurs rénales



Gill I.S., Aron M., Gervais D.A., Jewett M.A. Clinical practice. Small renal mass N Engl J Med 2010 ;  362 : 624-634 [cross-ref]

La néphrectomie radicale pour le traitement des cancers du rein non métastatiques



Robson C.J., Churchill B.M., Anderson W. The results of radical nephrectomy for renal cell carcinoma Journal of Urology 1969 ;  101 : 297-301 [cross-ref]
Clayman R.V., Kavoussi L.R., Soper N.J., Dierks S.M., Meretyk S., Darcy M.D., et al. Laparoscopic nephrectomy: initial case report J Urol 1991 ;  146 : 278-282 [cross-ref]
Borin J.F. Laparoscopic radical nephrectomy: long-term outcomes Curr Opin Urol 2008 ;  18 : 139-144 [cross-ref]
Berger A., Brandina R., Atalla M.A., Herati A.S., Kamoi K., Aron M., et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more J Urol 2009 ;  182 : 2172-2176 [cross-ref]
Gabr A.H., Gdor Y., Strope S.A., Roberts W.W., Wolf J.S. Patient and pathologic correlates with perioperative and long-term outcomes of laparoscopic radical nephrectomy Urology 2009 ;  74 : 635-640 [inter-ref]
Colombo J.R., Haber G.P., Jelovsek J.E., Lane B., Novick A.C., Gill I.S. Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes Urology 2008 ;  71 : 1149-1154 [inter-ref]
Hemal A.K., Kumar A., Kumar R., Wadhwa P., Seth A., Gupta N.P. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison J Urol 2007 ;  177 : 862-866 [cross-ref]
O’Malley R.L., Godoy G., Kanofsky J.A., Taneja S.S. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review J Urol 2009 ;  181 : 2009-2017
Ito K., Nakazawa H., Marumo K., Ozono S., Igarashi T., Shinohara N., et al. Risk factors for ipsilateral adrenal involvement in renal cell carcinoma Urology 2008 ;  72 : 354-358 [inter-ref]
Tsui K.H., Shvarts O., Barbaric Z., Figlin R., de Kernion J.B., Belldegrun A. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies J Urol 2000 ;  163 : 437-441 [cross-ref]
Blom J.H., van Poppel H., Marechal J.M., Jacqmin D., Sylvester R., Schroder F.H., et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group Eur Urol 1999 ;  36 : 570-575 [cross-ref]
Blom J.H., van Poppel H., Marechal J.M., Jacqmin D., Schroder F.H., de Prijck L., et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881 Editorial by Urs E. Studer and Frederic D. Birkhauser on pp. x-y of this issue Eur Urol 2008 ;  55 : 28-34
Zini L., Perrotte P., Jeldres C., Capitanio U., Pharand D., Arjane P., et al. Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma BJU Int 2008 ;  102 : 1610-1614 [cross-ref]
Guzzo T.J., Schaeffer E.M., McNeil B.K., Pollock R.A., Pavlovich C.P., Allaf M.E. Laparoscopic radical nephrectomy for patients with pathologic T3b renal-cell carcinoma: the Johns Hopkins experience J Endourol 2009 ;  23 : 63-67
Ciancio G., Soloway M., Livingstone A.S. The increasing use of liver transplantation surgical techniques in the management of renal and nonrenal cancer with or without inferior vena cava tumor thrombus World J Surg 2009 ;  33 : 1328-1329author reply 1330-21.
 [cross-ref]
Zini L., Haulon S., Decoene C., Amara N., Villers A., Biserte J., et al. Renal cell carcinoma associated with tumor thrombus in the inferior vena cava: surgical strategies Ann Vasc Surg 2005 ;  19 : 522-528 [cross-ref]
Rigaud J., Hetet J.F., Braud G., Battisti S., Le Normand L., Glemain P., et al. Surgical care, morbidity, mortality and follow-up after nephrectomy for renal cancer with extension of tumor thrombus into the inferior vena cava: retrospective study since 1990s Eur Urol 2006 ;  50 : 302-310 [cross-ref]
Margulis V., Sanchez-Ortiz R.F., Tamboli P., Cohen D.D., Swanson D.A., Wood C.G. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management Cancer 2007 ;  109 : 2025-2030 [cross-ref]
Capitanio U., Perrotte P., Zini L., Jeldres C., Shariat S.F., Isbarn H., et al. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma) BJU Int 2009 ;  104 : 795-799 [cross-ref]
Lam J.S., Shvarts O., Pantuck A.J. Changing concepts in the surgical management of renal cell carcinoma Eur Urol 2004 ;  45 : 692-705 [cross-ref]

Les approches adjuvantes et néo-adjuvantes dans les cancers du rein localisés à risque et localement avancés



Lam J.S., Klatte T., Kim H.L., Patard J.J., Breda A., Zisman A., et al. Prognostic factors and selection for clinical studies of patients with kidney cancer Crit Rev Oncol Hematol 2008 ;  65 : 235-262 [cross-ref]
Frank I., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 2002 ;  168 : 2395-2400 [cross-ref]
Zisman A., Pantuck A.J., Dorey F., Said J.W., Shvarts O., Quintana D., et al. Improved prognostication of renal cell carcinoma using an integrated staging system Journal of Clinical Oncology 2001 ;  19 : 1649-1657 [cross-ref]
Karakiewicz P.I., Briganti A., Chun F.K., Trinh Q.D., Perrotte P., Ficarra V., et al. Multi-institutional validation of a new renal cancer-specific survival nomogram J Clin Oncol 2007 ;  25 : 1316-1322 [cross-ref]
Messing E.M., Manola J., Wilding G., Propert K., Fleischmann J., Crawford E.D., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/InterGroup trial J Clin Oncol 2003 ;  21 : 1214-1222 [cross-ref]
Pizzocaro G., Piva L., Colavita M., Ferri S., Artusi R., Boracchi P., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study J Clin Oncol 2001 ;  19 : 425-431 [cross-ref]
Clark J.I., Atkins M.B., Urba W.J., Creech S., Figlin R.A., Dutcher J.P., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working Group randomized trial J Clin Oncol 2003 ;  21 : 3133-3140 [cross-ref]
Atzpodien J., Kirchner H., Jonas U., Bergmann L., Schott H., Heynemann H., et al. Interleukin-2 – and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) J Clin Oncol 2004 ;  22 : 1188-1194 [cross-ref]
Atzpodien J., Schmitt E., Gertenbach U., Fornara P., Heynemann H., Maskow A., et al. Adjuvant treatment with interleukin-2 – and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Br J Cancer 2005 ;  92 : 843-846 [cross-ref]
Jocham D., Richter A., Hoffmann L., Iwig K., Fahlenkamp D., Zakrzewski G., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 2004 ;  363 : 594-599 [cross-ref]
Wood C., Srivastava P., Bukowski R., Lacombe L., Gorelov A.I., Gorelov S., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96;vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 2008 ;  372 : 145-154 [cross-ref]
Wood C.G. Adjuvant approaches to renal cell carcinoma Clin Adv Hematol Oncol 2008 ;  6 : 19-21
Thomas A.A., Rini B.I., Lane B.R., Garcia J., Dreicer R., Klein E.A., et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 2009 ;  181 : 518-523discussion 523.
 [cross-ref]
van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., Bex A., de Gast G., Haanen J.B., et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 2008 ;  14 : 2431-2436 [cross-ref]
Jonasch E., Wood C.G., Matin S.F., Tu S.M., Pagliaro L.C., Corn P.G., et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 2009 ;  27 : 4076-4081 [cross-ref]
Cowey C.L., Amin C., Pruthi R.S., Wallen E.M., Nielsen M.E., Grigson G., et al. Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma J Clin Oncol 2010 ;  28 : 1502-1507 [cross-ref]
Wood L., Garcia J.A., Elson P., Salas R.N., Lane B.R., Klein E., et al. Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC) J Clin Oncol 2009 ;  27 : 5096[Abstract].

Prise en charge du cancer du rein métastatique - Place de la chirurgie des métastases



Russo P. Multi-modal treatment for metastatic renal cancer: the role of surgery World J Urol 2010 ;  28 : 295-301 [cross-ref]
Kavolius J.P., Mastorakos D.P., Pavlovich C., Russo P., Burt M.E., Brady M.S. Resection of metastatic renal cell carcinoma J Clin Oncol 1998 ;  16 : 2261-2266 [cross-ref]
Murthy S.C., Kim K., Rice T.W., Rajeswaran J., Bukowski R., DeCamp mm., et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 2005 ;  79 : 996-1003 [cross-ref]
Reddy S., Wolfgang C.L. The role of surgery in the management of isolated metastases to the pancreas Lancet Oncol 2009 ;  10 : 287-293 [inter-ref]
Kopke T., Bierer S., Wulfing C., Tiemann A., Hertle L., Herrmann E. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents Expert Rev Anticancer Ther 2009 ;  9 : 763-771 [cross-ref]

Rôle de la néphrectomie en situation métastatique



Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 2001 ;  345 : 1655-1659 [cross-ref]
Lara P.N., Tangen C.M., Conlon S.J., Flanigan R.C., Crawford E.D. Predictors of survival of advanced renal cell carcinoma: longterm results from Southwest Oncology Group Trial S8949 J Urol 2009 ;  181 : 512-516discussion 516-7.
 [cross-ref]
Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: a randomised trial Lancet 2001 ;  358 : 966-970 [cross-ref]
Zini L., Capitanio U., Perrotte P., Jeldres C., Shariat S.F., Arjane P., et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma Urology 2009 ;  73 : 342-346 [cross-ref]
Szczylik C., Porta C., Bracarda S., Hawkins R., Bjarnason G.A., Oudard S., et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC) J Clin Oncol 2008 ;  26 : 5124[Abstract].
Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 2007 ;  356 : 2271-2281 [cross-ref]
Logan T., McDermott D.F., Dutcher J.P., Makhson A., Mikulas J., Berkenblit A., et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features J Clin Oncol 2008 ;  26 : 5050[Abstract].
Rini B.I., Campbell S.C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 2007 ;  177 : 1978-1984 [cross-ref]

Traitement médical du cancer du rein métastatique



Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 2001 ;  345 : 1655-1659 [cross-ref]
Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R.European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 2001 ;  358 : 966-970 [cross-ref]
Thomas A.A., Rini B.I., Stephenson A.J., Garcia J.A., Fergany A., Krishnamurthi V., et al. Surgical resection of renal cell carcinoma after targeted therapy J Urol 2009 ;  182 : 881-886 [cross-ref]
Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 2007 ;  370 : 2103-2111 [cross-ref]
Escudier B., Bellmunt J., Négrier S., Bajetta E., Melichar B., Bracarda S., et al. A Phase III Trial of Bevacizumab Plus Interferon-2a in Patients with Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival J Clin Oncol 2010 ;  28 : 2144-2150 [cross-ref]
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 2007 ;  356 : 115-124 [cross-ref]
Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 2010 ;  28 : 1061-1068 [cross-ref]
Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 2007 ;  356 : 2271-2281 [cross-ref]
Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007 ;  356 : 125-134 [cross-ref]
Motzer R.J., Escudier B., Oudard S., et al. Everolimus for advanced renal cell carcinoma Lancet 2008 ;  372 : 449-456 [cross-ref]
Choueiri T.K., Plantade A., Elson P., Negrier S., Ravaud A., Oudard S., et al. Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma J Clin Oncol 2008 ;  26 : 127-131 [cross-ref]
Oudard S., Banu E., Vieillefond A., Fournier L., Priou F., Medioni J., et al. Prospective multicenter phase II study of Gemcitabine plus Platinum salt in metastatic collecting duct carcinoma patients. Results of a GETUG study J Urol 2007 ;  177 : 1698-1702 [cross-ref]

Suivi du cancer du rein après traitement chirurgical curatif



Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 2003 ;  30 : 843-852 [inter-ref]
Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer Statistics, 2008 CA Cancer J Clin 2008 ;  58 : 71-96 [cross-ref]
Breda A., Konijeti R., Lam J.S. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection Expert Rev Anticancer Ther 2007 ;  7 : 847-862 [cross-ref]
Tollefson M.K., Takahashi N., Leibovich B.C. Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma Curr Urol Rep 2007 ;  8 : 38-43 [cross-ref]
Antonelli A., Cozzoli A., Zani D., Zanotelli T., Nicolai M., Cunico S.C., et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol BJU Int 2007 ;  99 : 296-300 [cross-ref]
Dimarco D.S., Lohse cm, Zincke H., Cheville J.C., Blute M.L. Longterm survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy Urology 2004 ;  64 : 462-467 [inter-ref]
Eggener S.E., Yossepowitch O., Pettus J.A., Snyder M.E., Motzer R.J., Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence J Clin Oncol 2006 ;  24 : 3101-3106 [cross-ref]
Ljungberg B., Alamdari F.I., Rasmuson T., Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy BJU Int 1999 ;  84 : 405-411
Herold C.J., Bankier A.A., Fleischmann D. Lung metastases Eur Radiol 1996 ;  6 : 596-606
Cindolo L., Patard J.J., Chiodini P., Schips L., Ficarra V., Tostain J., et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study Cancer 2005 ;  104 : 1362-1371 [cross-ref]
Patard J.J., Kim H.L., Lam J.S., Dorey F.J., Pantuck A.J., Zisman A., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study J Clin Oncol 2004 ;  22 : 3316-3322 [cross-ref]
Zisman A., Pantuck A.J., Dorey F., Said J.W., Shvarts O., Quintana D., et al. Improved prognostication of renal cell carcinoma using an integrated staging system Journal of Clinical Oncology 2001 ;  19 : 1649-1657 [cross-ref]
Huang W.C., Levey A.S., Serio A.M., Snyder M., Vickers A.J., Raj G.V., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study Lancet Oncol 2006 ;  7 : 735-740 [inter-ref]
Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 2004 ;  351 : 1296-1305 [cross-ref]
Weight C.J., Larson B.T., Fergany A.F., Gao T., Lane B.R., Campbell S.C., et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses J Urol 2010 ;  183 : 1317-1323 [cross-ref]
Lau W.K., Blute M.L., Weaver A.L., Torres V.E., Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney Mayo Clin Proc 2000 ;  75 : 1236-1242 [cross-ref]
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 2002 ;  39 : S1-S266






© 2010 
Elsevier Masson SAS. Tous droits réservés.